Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor

17 Jul 2023

Abstract excerpt

Epigenetic modifiers of the histone deacetylase (HDAC) family are often dysregulated in cancer cells. Experiments with small molecule HDAC inhibitors (HDACi) have proven that HDACs are a vulnerability of transformed cells. We evaluated a novel hydroxamic acid-based HDACi (KH16; termed yanostat) in human pancreatic ductal adenocarcinoma (PDAC) cells, short- and long-term cultured colorectal cancer (CRC) cells, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37509312
DOI: 10.3390/cancers15143650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase InhibitorPMID 37509312Read ↗

Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cellsSemantic proximity Read ↗

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancerSemantic proximity Read ↗

Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1ASemantic proximity Read ↗

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylaseSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersSemantic proximity Read ↗

Histone Deacetylase Inhibitors in Cancer TherapySemantic proximity Read ↗

Differential Transcriptomic Modulation by Histone Deacetylase Inhibitor SAHA in LUAD and LUSCSemantic proximity Read ↗

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancerSemantic proximity Read ↗

The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.Semantic proximity Read ↗

HDAC11 is a novel drug target in carcinomasSemantic proximity Read ↗

Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.Semantic proximity Read ↗

Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.